Prostate Cancer Clinical Trials in Nashville

Showing 181-200 of 306 trials

PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

NCT05447637

This registry is for men who have prostate cancer and have had multigene panel hereditary testing. The registry will gather data on genetic testing results and how that information may change physician treatment or follow up recommendations. It will also gather data on the patient's experience with genetic testing, through a post-test survey to be completed 60-90days after results have been received and discussed with their provider.

Prostate Cancer

Invitae Corporation1,000 participantsStarted Nov 2019

San Diego, California, United States • San Francisco, California, United States • San Francisco, California, United States +16 more locations

COMPLETEDPhase 3< 1 mile

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

NCT00002874

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using bicalutamide may fight prostate cancer by reducing the production of androgens. It is not yet known if radiation therapy is more effective with or without bicalutamide for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without bicalutamide in treating patients who have stage II or stage III prostate cancer and elevated prostate-specific antigen (PSA) levels following radical prostatectomy.

Prostate Cancer

Radiation Therapy Oncology Group840 participantsStarted Feb 1998

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Huntsville, Alabama, United States +237 more locations

PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

Prostate Cancer Trials in Other Cities

Safety Study of MGA271 in Refractory Cancer

Vinflunine in Hormone Refractory Prostate Cancer (HRPC)

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Radiation Therapy in Treating Patients With Prostate Cancer

Perioperative Post-Prostatectomy Incontinence Home Telehealth Program

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Other Conditions in Nashville